

PATENT  
Attorney Docket No. 219603  
Client Reference No. KAUS430501

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**RECEIVED**

In re Application of:

NOV 24 2003

Kasid et al.

Art Unit: 1635

Application No.: 09/930,283

Examiner: T. Gibbs

Filed: August 16, 2001

TECH CENTER 1600/2900

For: LIPOSOMES CONTAINING  
OLIGONUCLEOTIDES**RESPONSE TO OFFICE ACTION**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

In response to the Office Action dated August 26, 2003, please enter the following amendments and consider the following remarks.

<b>CERTIFICATE OF MAILING OR TRANSMISSION UNDER 37 CFR 1.8</b>			
I hereby certify that this Response to Office Action and all accompanying documents are, on the date indicated below, <input checked="" type="checkbox"/> being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or <input type="checkbox"/> being facsimile transmitted to the U.S. Patent and Trademark Office, Attention: Examiner T. Gibbs, Art Unit 1635. Facsimile Number _____			
Name (Print/Type)	M. Daniel Hefner		
Signature		Date	September 11, 2003

In re Appln. of Kasid et al.  
Application No. 09/930,283

*Amendments to the Abstract:*

Please replace the paragraph appearing on page 31 of the application under the section heading "Abstract" with the following (note the underlining of "c-raf-1" in the second line is formatting from the original; it does not signify an amendment):

It is possible to radiosensitize tumor cells by administration of compositions containing the Human antisense c-raf-1 oligodeoxyribonucleotide (ODN/oligo) sequence: 5'-GTGCTCCATTGATGC-3' (see #1) (SEQ ID NO: 1) wherein only the end bases are phosphorylated in a preferred embodiment. Antisense sequences of up to 40 bases which containing this sequence may be used in accord with the teachings of this disclosure. Compositions comprising a cationic liposome of dimethyldioctadecyl ammonium bromide, phosphatidylcholine and cholesterol may be used as a carrier system. The liposomes provide a new carrier system that is particularly useful for administration of sequences for therapy.